Bethesda, Maryland 20892

  • Neurofibromatosis Type


RATIONALE: Learning about neurobehavioral function and quality of life over time in patients with cancer or other chronic disease may help doctors learn about the long-term effects of treatment and plan the best treatment. PURPOSE: This clinical trial is collecting and storing information over time from patients with cancer or other chronic disease who have undergone neurobehavioral assessments on another clinical trial.

Study summary:

OBJECTIVES: Primary - Determine the neurobehavioral function of patients with chronic illness by analyzing stored data collected from IRB-approved protocols comprising retrospective data collected on protocols that are now closed and prospective data from current and future protocols. Secondary - Determine the relationship between neurobehavioral functioning and medical, neuroimaging, neurologic, and psychiatric variables in these patients. - Determine the association of neurobehavioral functioning and medication adherence, life events, and family functioning in these patients. - Compare neurobehavioral measures between different subgroups within an illness group. - Determine the effects of treatment (e.g., antiretroviral therapy, radiation therapy) on neurobehavioral functioning over time in these patients. - Compare the responses of patients and caregivers on behavioral, adherence, and quality of life questionnaires. - Compare various aspects of neurobehavioral functioning between patients with different chronic medical conditions. - Validate novel assessment tools developed to better measure specific domains of functioning, such as quality of life and neurologic function in children with chronic illnesses with possible CNS involvement. OUTLINE: This is a longitudinal, retrospective, and prospective study. Retrospective data previously collected from patients enrolled on IRB-approved protocols is identified from the secure NCI/Medical Illness Counseling Center (MICC) neuropsychological database. Prospective data is collected from patients as specified in current or future IRB-approved protocols and entered in the secure NCI/MICC neuropsychological database within 1 month of assessment. Retrospective and prospective data collected from multisite IRB-approved protocols, that have a CCR investigator and the neurobehavioral data managed by NCI, may be included in analyses when appropriate. Various cross-sectional and/or longitudinal analyses are conducted on the selected data in the NCI/MICC neuropsychological database when appropriate. PROJECTED ACCRUAL: A total of 300 patients will be accrued for this study.


DISEASE CHARACTERISTICS: - Any of the following diagnoses are allowed: - HIV positivity - Cancer (especially brain tumors and leukemia) - Neurofibromatosis type 1 - Data obtained from infants, children, adolescents, and adults who underwent neurobehavioral assessments as part of a past, current, or future IRB-approved protocol - No CNS condition (i.e., Down syndrome, severe intraventricular hemorrhage) not related to primary medical diagnosis (i.e., HIV, cancer) that may affect neurobehavioral functioning, missing values on a particular test being studied, or invalid data as determined by the investigator PATIENT CHARACTERISTICS: - Not specified PRIOR CONCURRENT THERAPY: - Not specified

Study is Available At:

Original ID:

070110, CDR0000538241



Secondary ID:


Study Acronym:

Brief Title:

Collecting and Storing Information From Patients With Cancer or Other Chronic Disease Who Have Undergone Neurobehavioral Assessments on Another Clinic

Official Title:

Analysis of Stored Data Collected From Individuals Administered Neurobehavioral Assessments on IRB-Approved Protocols

Overall Status:


Study Phase:




Minimum Age:


Maximum Age:


Quick Facts

Healthy Volunteers
Oversight Has DMC
Study Is FDA Regulated
Study Is Section 801
Has Expanded Access

Study Source:

National Institutes of Health Clinical Center (CC)

Oversight Authority:

There was an error processing this request

Reasons Why Stopped:

Study Type:


Study Design:


Number of Arms:


Number of Groups:


Total Enrollment:


Enrollment Type:


Overall Contact Information

Official Name:Pam Wolters, PhD
Study Chair
National Cancer Institute (NCI)

Study Dates

Start Date:January 2007
Verification Date:September 2011
Last Changed Date:September 29, 2011
First Received Date:April 9, 2007

Study Outcomes

Outcome Type:Primary Outcome
Measure:Neurobehavioral function
Safety Issues:False
Outcome Type:Secondary Outcome
Measure:Relationship between neurobehavioral test scores, medical variables, environmental factors, and demographic characteristics
Safety Issues:False
Outcome Type:Secondary Outcome
Measure:Comparison of neurobehavioral measures between different subgroups of patients with varying levels of clinical, immunological, and virologic status
Safety Issues:False
Outcome Type:Secondary Outcome
Measure:Changes in psychometric test scores over time
Safety Issues:False

Study Interventions

Intervention Type:Other
Name:physiologic testing
Intervention Type:Procedure
Name:cognitive assessment
Intervention Type:Procedure
Name:management of therapy complications
Intervention Type:Procedure
Name:psychosocial assessment and care
Intervention Type:Procedure
Name:quality-of-life assessment

Study Arms

There are no available Study Arms

Study Agencies

Agency Class:NIH
Agency Type:Lead Sponsor
Agency Name:National Cancer Institute (NCI)

Sample and Retention Information

There are no available Sample and Retention Information

Study References

There are no available Study References

Data Source:

Date Processed: February 08, 2023

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

This study is not currently recruiting Study Participants. The form below is not enabled.